JP2017502278A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017502278A5 JP2017502278A5 JP2016539206A JP2016539206A JP2017502278A5 JP 2017502278 A5 JP2017502278 A5 JP 2017502278A5 JP 2016539206 A JP2016539206 A JP 2016539206A JP 2016539206 A JP2016539206 A JP 2016539206A JP 2017502278 A5 JP2017502278 A5 JP 2017502278A5
- Authority
- JP
- Japan
- Prior art keywords
- laccer
- inhibitor
- subject
- pharmaceutical composition
- spms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361963738P | 2013-12-12 | 2013-12-12 | |
| US61/963,738 | 2013-12-12 | ||
| US201462049813P | 2014-09-12 | 2014-09-12 | |
| US62/049,813 | 2014-09-12 | ||
| PCT/US2014/070099 WO2015089443A2 (en) | 2013-12-12 | 2014-12-12 | Treating neurodegenerative disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017502278A JP2017502278A (ja) | 2017-01-19 |
| JP2017502278A5 true JP2017502278A5 (enExample) | 2018-02-01 |
| JP6550388B2 JP6550388B2 (ja) | 2019-07-24 |
Family
ID=53371971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016539206A Expired - Fee Related JP6550388B2 (ja) | 2013-12-12 | 2014-12-12 | 神経変性疾患の治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9927437B2 (enExample) |
| EP (1) | EP3080602B1 (enExample) |
| JP (1) | JP6550388B2 (enExample) |
| KR (1) | KR20160089528A (enExample) |
| CN (1) | CN106030302B (enExample) |
| CA (1) | CA2933554A1 (enExample) |
| WO (1) | WO2015089443A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10512656B2 (en) | 2016-04-21 | 2019-12-24 | Baylor College Of Medicine | Compositions and methods for the treatment of lysosomal storage disorders and disorders characterized by lysosomal dysfunction |
| JP7084689B2 (ja) * | 2016-12-08 | 2022-06-15 | 公益財団法人東京都医学総合研究所 | 脳組織の異常を伴う非ヒト動物の作製方法およびその利用 |
| WO2019030645A1 (en) * | 2017-08-08 | 2019-02-14 | Kashiv Pharma Llc | Pharmaceutical composition comprising eliglustat |
| JP2021515037A (ja) | 2018-02-26 | 2021-06-17 | アントルクス，インコーポレーテッド | 寛容原性リポソーム及びその使用方法 |
| WO2019169317A1 (en) * | 2018-03-02 | 2019-09-06 | Stueve Olaf | Methods and compositions for treating natalizumab-associated progressive multifocal encephalopathy |
| EP3833398A4 (en) * | 2018-09-21 | 2021-12-22 | University of Connecticut | COMPOSITIONS AND METHODS OF RESTORING PATERNAL UBE3A GENE EXPRESSION IN ANGELMAN'S SYNDROME IN HUMANS |
| CN114717232A (zh) * | 2020-12-22 | 2022-07-08 | 未来智人再生医学研究院(广州)有限公司 | 表达irf-1靶向抑制因子的多能干细胞及其衍生物与应用 |
| CN116794308B (zh) * | 2023-07-20 | 2026-05-26 | 中国药科大学 | β-1,4-半乳糖基转移酶1及其抑制剂在制备治疗急慢性肝病药物中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5700909A (en) * | 1993-07-30 | 1997-12-23 | The Regents Of The University Of California | Prosaposin and cytokine-derived peptides |
| EP1825853A2 (en) * | 1998-07-27 | 2007-08-29 | Johns Hopkins University | Methods for treating conditions modulated by lactosyceramide |
| US20070270350A1 (en) * | 2003-12-23 | 2007-11-22 | Musc Foundation For Research Development | Methods and Compositions for the Prevention and Treatment of Inflammatory Diseases or Conditions |
| FR2869915B1 (fr) * | 2004-05-07 | 2006-08-18 | Merck Sante Soc Par Actions Si | Gm3 synthase, comme cible therapeutique dans les complications microvasculaires du diabete |
| WO2005123055A2 (en) * | 2004-06-14 | 2005-12-29 | Musc Foundation For Research Development | Methods for treating inflammatory disorders |
| US7572592B2 (en) * | 2005-01-31 | 2009-08-11 | Glycominds Ltd | Method for diagnosing multiple sclerosis |
| US8263576B2 (en) * | 2006-08-15 | 2012-09-11 | Mayo Foundation For Medical Education And Research | Non-natural sphingolipid analogs and uses thereof |
| EP2353004B1 (en) | 2008-11-12 | 2018-01-03 | Yeda Research and Development Co. Ltd. | Diagnosis of multiple sclerosis |
| US20120128665A1 (en) * | 2010-11-18 | 2012-05-24 | Synta Pharmaceuticals Corp. | Preselection of subjects for therapeutic treatment based on hypoxic status |
| AU2011349256B2 (en) * | 2010-12-20 | 2017-01-05 | Scidec Therapeutics, Inc. | Methods for treating neurological conditions and compositions and materials therefor |
| CN102994554A (zh) * | 2011-09-15 | 2013-03-27 | 花王株式会社 | 神经酰胺和/或葡萄糖神经酰胺产生促进剂的制造方法 |
| CN103059160B (zh) * | 2011-10-20 | 2015-12-02 | 中国科学院上海药物研究所 | β-葡聚糖GFPBW1及其制备方法和用途 |
-
2014
- 2014-12-12 WO PCT/US2014/070099 patent/WO2015089443A2/en not_active Ceased
- 2014-12-12 CN CN201480075396.4A patent/CN106030302B/zh active Active
- 2014-12-12 US US15/103,632 patent/US9927437B2/en active Active
- 2014-12-12 KR KR1020167018593A patent/KR20160089528A/ko not_active Abandoned
- 2014-12-12 JP JP2016539206A patent/JP6550388B2/ja not_active Expired - Fee Related
- 2014-12-12 CA CA2933554A patent/CA2933554A1/en not_active Abandoned
- 2014-12-12 EP EP14868919.3A patent/EP3080602B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sale et al. | Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors | |
| Watanabe et al. | Efficacy and safety of fosravuconazole L‐lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: a multicenter, double‐blind, randomized phase III study | |
| Camphausen et al. | Inhibition of histone deacetylation: a strategy for tumor radiosensitization | |
| Charifson et al. | Acidic and basic drugs in medicinal chemistry: a perspective | |
| Evageliou et al. | Polyamine antagonist therapies inhibit neuroblastoma initiation and progression | |
| Bandyopadhyay et al. | Novel 5′ untranslated region directed blockers of iron-regulatory protein-1 dependent amyloid precursor protein translation: implications for down syndrome and Alzheimer's disease | |
| Tremont-Lukats et al. | Advances in molecular therapies in patients with brain tumors | |
| Pagoria et al. | Antimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients | |
| TWI620748B (zh) | 氨基噻唑化合物及其用途 | |
| Botz et al. | Challenges to develop novel anti‐inflammatory and analgesic drugs | |
| Chan et al. | RETRACTED ARTICLE: Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer | |
| JP2017515893A5 (enExample) | ||
| JP2009541489A5 (enExample) | ||
| JP2016516074A5 (enExample) | ||
| JP2021193105A (ja) | Ｅｔｃ１００２及びエゼチミブを含む固定用量組合せ物及び製剤並びに心血管疾患を処置するか又は心血管疾患のリスクを低減させる方法 | |
| WO2016200726A1 (en) | Inhibitors of mci-1 as drugs to overcome resistance to braf inhibitors and mek inhibitors | |
| JP2018519324A5 (enExample) | ||
| Zhou et al. | Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma | |
| JP2011525174A5 (enExample) | ||
| US9552457B2 (en) | Reprogramming effector protein interactions to correct epigenetic defects in cancer | |
| US20140179743A1 (en) | Non-atp dependent inhibitors of extracellular signal-regulated kinase (erk) | |
| Kuang et al. | Discovery of oxazole-based PDE4 inhibitors with picomolar potency | |
| WO2024155965A3 (en) | Biomarkers for use in integrin inhibitor therapy | |
| Murai et al. | Relationship between serotonin transporter occupancies and analgesic effects of AS1069562, the (+)-isomer of indeloxazine, and duloxetine in reserpine-induced myalgia rats | |
| HK1259445A1 (zh) | 治疗癌症的组合 |